Ribociclib (RIB) fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR ), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.
DOI: 10.1200/jco.2018.36.15_suppl.1000
文献链接: http://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.1000
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Dennis J. Slamon; Patrick Neven; Stephen K. L. Chia; Seock-Ah Im; Peter A. Fasching; Michelino DeLaurentiis; Katarina Petrakova; Giulia Valeria Bianchi; Francisco J. Esteva; Miguel Martin; Xavier Pivot; Gena Vidam; Yingbo Wang; Cristina Karen Rodriguez Lorenc; Michelle Kristine Miller; Tanya Taran; Guy Heinrich Maria Jerusalem
需要全文和补充材料,二者都要

